• If you are wondering whether Catalyst Pharmaceuticals' current share price still offers value, you are not alone. The stock has attracted attention from investors trying to work out if it is priced fairly.
• The share price closed at US$23.23 recently, with returns of a 4.2% decline over 7 days, a 2.9% decline over 30 days, a 0.3% gain year to date, 10.5% over 1 year, 45.9% over 3 years and a very large gain over 5 years.
• Recent coverage has focused on the company as part of wider discussions around smaller pharmaceutical and biotech names, with investors watching how firms in this space manage product portfolios and regulatory milestones. This context helps frame the current trading range, as sentiment in the sector can influence how much investors are willing to pay for companies like Catalyst Pharmaceuticals.
• On our valuation framework Catalyst Pharmaceuticals currently scores 6 out of 6 for being undervalued on each of our checks. Next we will walk through what that means across different valuation methods, before finishing with a tool that can help you judge value even more clearly for yourself.

Approach 1: Catalyst Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes forecasts of a company’s future cash flows and discounts them back to today’s value, so you can compare that estimate with the current share price.

For Catalyst Pharmaceuticals, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is US$129.36 million. Analysts and internal estimates project free cash flow reaching US$384.83 million in 2035, with a ten year path that includes forecast figures such as US$221 million in 2026 and US$340 million in 2030. Simply Wall St only uses analyst inputs where available and then extrapolates further years to complete the curve.

After discounting all projected cash flows back to today, the model arrives at an estimated intrinsic value of US$63.78 per share for Catalyst Pharmaceuticals. Compared with the recent share price of US$23.23, this DCF output implies the stock is 63.6% undervalued on this framework.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Catalyst Pharmaceuticals is undervalued by 63.6%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.

Approach 2: Catalyst Pharmaceuticals Price vs Earnings

P/E is a common yardstick for valuing profitable companies because it links what you pay for each share to the earnings that company is currently generating. It gives you a quick sense of how many dollars investors are willing to pay today for one dollar of earnings.

What counts as a “normal” P/E depends on how the market views a company’s growth prospects and risk. Higher expected growth or lower perceived risk can justify a higher P/E, while lower growth or higher risk usually point to a lower P/E.

Catalyst Pharmaceuticals currently trades on a P/E of 13.24x. That sits below the Biotechs industry average of 20.88x and also below the peer group average of 32.85x. Simply Wall St’s Fair Ratio for the stock is 16.16x, which is the P/E level its model suggests given factors such as earnings growth, industry, profit margins, market cap and risk profile.

The Fair Ratio is more tailored than a simple peer or industry comparison, because it folds in those company specific drivers rather than assuming all firms deserve the same multiple. With Catalyst Pharmaceuticals trading at 13.24x versus a Fair Ratio of 16.16x, the shares screen as undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Catalyst Pharmaceuticals Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. These are simply your story about a company, linked to your own view of its future revenue, earnings and margins, and then translated into a fair value that you can compare with today’s price.

On Simply Wall St’s Community page, millions of investors use Narratives as an easy tool to connect the company story with a set of financial forecasts. This allows you to quickly see whether your fair value sits above or below the current share price and decide if that points you toward buying, selling or waiting.

Narratives also update automatically as new information such as earnings releases or news comes through. This means your fair value view can stay aligned with the latest data instead of a one off spreadsheet exercise.

For Catalyst Pharmaceuticals, one investor might build a Narrative that leans toward the higher analyst fair value view around US$40.00 because they focus on expansion of the rare disease portfolio. Another might anchor closer to the lower US$31.00 view because they are more cautious about FIRDAPSE concentration, generic risks and rising expenses.

Do you think there's more to the story for Catalyst Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.